This was the stock's second consecutive day of losses.

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

User Agreement; Privacy Policy; Ad Choices; Site Map © 2025 American City Business Journals. All rights reserved. Use of ...

The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused ...

Novavax, Inc. (Nasdaq: NVAX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Nuvaxovid™ for active immunization to ...

The FDA approved Moderna’s new Covid-19 vaccine late Friday, though it placed restrictions on its use that the company’s ...

Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's Covid-19 vaccine after more than a month of delay b ...

Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to grant Novavax full approval – without restrictions -- by its April 1 target ...

Short interest in Novavax Inc (NASDAQ:NVAX) increased during the last reporting period, rising from 42.33M to 46.47M. This put 28.79% of the company's publicly available shares short. Short ...

Shares of Novavax Inc. NVAX shed 1.52% to $7.15 Wednesday, on what proved to be an all-around mixed trading session for the ...

The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay.